Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

News Conference News VEITH 2019

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

L.A. McKeown

November 22, 2019

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

Presentation TCT 2019

Sustained Limus Release-Designed Drug-Eluting Balloons: Is This the Solution for the Potential Increased Mortality With Paclitaxel Devices When Treating the SFA?

Presenter: Thomas Zeller

September 27, 2019

Presentation TCT 2019

Treating Challenging SFA Disease in the Era of Paclitaxel Uncertainty

Presenter: Aravinda Nanjundappa

September 27, 2019

Presentation TCT 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presenter: Ian Meredith AM

September 26, 2019

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

Presentation TCT 2019

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Presenter: Krishna Rocha-Singh

September 26, 2019

Presentation TCT 2019

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Presenter: Konstantinos Katsanos

September 26, 2019

Presentation TCT 2019

Intravascular Ultrasound Supported Endovascular Therapy in SFA Disease: 12-Month Results From the IVORY Study

Presenter: Osamu Iida

September 26, 2019

Presentation TCT 2019

Emerging Drug-Free Platforms for the SFA: Can We Do Better Off Drugs?

Presenter: William Gray

September 26, 2019

Presentation TCT 2019

Circumstances in Which I Feel That I Have to Use DCB/DES

Presenter: Ehrin Armstrong

September 26, 2019

Presentation TCT 2019

There Are No Circumstances in Which I Have to Use DCB/DES

Presenter: Konstantinos Katsanos

September 26, 2019

Presentation TCT 2019

Deciphering the FDA Guidance

Presenter: Mehdi Shishehbor

September 26, 2019

Presentation TCT 2019

Long Segment SFA CTO in a Claudicant

Presenter: Brian DeRubertis

September 26, 2019

Presentation TCT 2019

State of the Art Lecture: Novel Drug Delivery Technologies for the SFA

Presenter: Juan Granada

September 26, 2019

Presentation TCT 2019

Introduction and Session Objectives

Presenter: Sahil Parikh

September 26, 2019

Presentation TCT 2019

My Toughest SFA Case of the Year

Presenter: Subhash Banerjee

September 25, 2019

Presentation TCT 2019

Taking the Scenic Route: PQ Bypass for Extreme SFA Lesions

Presenter: Ehrin Armstrong

September 25, 2019

Advertisement

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

Sustained Limus Release-Designed Drug-Eluting Balloons: Is This the Solution for the Potential Increased Mortality With Paclitaxel Devices When Treating the SFA?

Treating Challenging SFA Disease in the Era of Paclitaxel Uncertainty

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Intravascular Ultrasound Supported Endovascular Therapy in SFA Disease: 12-Month Results From the IVORY Study

Emerging Drug-Free Platforms for the SFA: Can We Do Better Off Drugs?

Circumstances in Which I Feel That I Have to Use DCB/DES

There Are No Circumstances in Which I Have to Use DCB/DES

Deciphering the FDA Guidance

Long Segment SFA CTO in a Claudicant

State of the Art Lecture: Novel Drug Delivery Technologies for the SFA

Introduction and Session Objectives

My Toughest SFA Case of the Year

Taking the Scenic Route: PQ Bypass for Extreme SFA Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content